SCHEMBL6610195

SCHEMBL6610195

COC(=O)C(CO)N(Cc1ccccc1NC(=O)N1CCOCC1)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 3/20 0.47
MMP1 P03956 2/20 0.46
MMP9 P14780 2/20 0.46
MMP13 P45452 2/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
KEAP1 Q14145 5/20 0.46
NFE2L2 Q16236 3/20 0.46
BLM P54132 1/20 0.45
HPGD P15428 2/20 0.44
CYP2C9 P11712 1/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.44
OPRK1 P41145 1/20 0.44
ADAM17 P78536 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6609503 0.82 BMP1 (0.52) BMP1MMP1MMP9MMP13MMP2
SCHEMBL6613444 0.80 KEAP1 (0.53) BMP1MMP1MMP9MMP13MMP2
SCHEMBL6610017 0.80 BLM (0.47) BMP1MMP1MMP9MMP13MMP3
SCHEMBL5655796 0.77 KEAP1 (0.56) BMP1MMP1MMP9MMP13MMP2
SCHEMBL5654237 0.75 MMP1 (0.69) MMP1MMP9MMP13MMP2KEAP1
SCHEMBL7349119 0.73 MMP3 (0.53) BMP1MMP1MMP9MMP13MMP2
SCHEMBL6610164 0.70 BMP1 (0.48) BMP1MMP1MMP9MMP13MMP2
SCHEMBL8023076 0.69 KEAP1 (0.46) BMP1MMP1MMP9MMP13MMP2
SCHEMBL6611787 0.69 KEAP1 (0.46) BMP1MMP1MMP9MMP13MMP2
SCHEMBL6611785 0.69 KEAP1 (0.46) BMP1MMP1MMP9MMP13MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed